Table 6. Demographic, clinical, and laboratory data for patients with and without advanced fibrosis.
| Adv. Fibrosis | none to minimal Fibrosis | P-value | Test | |
| N | 6 | 31 | ||
| NASH | 3 (50%) | 19 (61%) | 0.667 | FE |
| Diabetes | 3 (50%) | 10 (32%) | 0.664 | FE |
| Female | 4 (67%) | 21 (68%) | 1.00 | FE |
| Caucasian | 5 (83%) | 26 (84%) | 0.561 | Chi |
| Age | 51±10 | 48±10 | 0.483 | 2T |
| BMI | 48±2.6 | 48±11 | 0.564 | MW |
| Hyperlipidemia | 4 (67%) | 19 (61%) | 1.00 | FE |
| Hypertension | 6 (100%) | 20 (65%) | 0.244 | Chi |
| AST (U/L) | 20±2.4 | 23±7.2 | 0.042 | 2T |
| ALT (U/L) | 23±4.7 | 34±16 | 0.026 | MW |
| AST: ALT | 0.88±0.15 | 0.75±0.29 | 0.122 | MW |
| Albumin (g/dL) | 4.0±0.28 | 4.0±0.57 | 0.804 | MW |
| Bilirubin (total) (mg/dL) | 0.52±0.28 | 0.49±0.28 | 0.753 | MW |
| White blood cell count (103/uL) | 8.0±2.7 | 7.2±1.8 | 0.592 | MW |
| Platelet count (103/uL) | 256±99 | 276±69 | 0.649 | 2T |
| Hemoglobin (g/dL) | 12.4±1.8 | 13.6±1.2 | 0.156 | 2T |
| Glucose (mg/dL) | 103±41 | 113±39 | 0.606 | MW |
| Cholesterol (total) (mg/dL) | 203±15 | 185±36 | 0.065 | 2T |
| Triglycerides (mg/dL) | 144±39 | 183±131 | 0.853 | MW |
| HDL (mg/dL) | 56±7.8 | 47±9.8 | 0.041 | 2T |
| CCL-2 (pg/mL) | 390±103 | 488±169 | 0.161 | MW |
| sFasL (pg/mL) | 86±33 | 86±33 | 0.805 | MW |
| Portal fibrosis | 5 (83%) | 21 (68%) | 0.782 | Chi |
| Pericellular fibrosis | 3 (50%) | 9 (29%) | 0.367 | FE |
Entries are counts for discrete measures (with percentage of group total given in parentheses) or mean ± S.D. for continuous measures. A p-value of ≤0.05 was considered significant. Significant results are shown in bold text. Chi = chi square test of homogeneity; FE = Fisher’s exact test; MW = Mann-Whitney U test; 2T = two-sample t-test (2-tailed).